Cargando…

A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity

Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analog, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First...

Descripción completa

Detalles Bibliográficos
Autores principales: Ózsvári, Béla, Magalhães, Luma G., Latimer, Joe, Kangasmetsa, Jussi, Sotgia, Federica, Lisanti, Michael P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523513/
https://www.ncbi.nlm.nih.gov/pubmed/33042796
http://dx.doi.org/10.3389/fonc.2020.01528
_version_ 1783588394314498048
author Ózsvári, Béla
Magalhães, Luma G.
Latimer, Joe
Kangasmetsa, Jussi
Sotgia, Federica
Lisanti, Michael P.
author_facet Ózsvári, Béla
Magalhães, Luma G.
Latimer, Joe
Kangasmetsa, Jussi
Sotgia, Federica
Lisanti, Michael P.
author_sort Ózsvári, Béla
collection PubMed
description Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analog, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First, we determined the IC(50) of Doxy-Myr using the 3D-mammosphere assay, to assess its ability to inhibit the anchorage-independent growth of breast CSCs, using MCF7 cells as a model system. Our results indicate that Doxy-Myr is >5-fold more potent than Doxycycline, as it appears to be better retained in cells, within a peri-nuclear membranous compartment. Moreover, Doxy-Myr did not affect the viability of the total MCF7 cancer cell population or normal fibroblasts grown as 2D-monolayers, showing remarkable selectivity for CSCs. Using both gram-negative and gram-positive bacterial strains, we also demonstrated that Doxy-Myr did not show antibiotic activity, against Escherichia coli and Staphylococcus aureus. Interestingly, other complementary Doxycycline amide derivatives, with longer (16 carbon; palmitic acid) or shorter (12 carbon; lauric acid) fatty acid chain lengths, were both less potent than Doxy-Myr for the targeting of CSCs. Finally, using MDA-MB-231 cells, we also demonstrate that Doxy-Myr has no appreciable effect on tumor growth, but potently inhibits tumor cell metastasis in vivo, with little or no toxicity. In summary, by using 9-amino-Doxycycline as a scaffold, here we have designed new chemical entities for their further development as anti-cancer agents. These compounds selectively target CSCs, e.g., Doxy-Myr, while effectively minimizing the risk of driving antibiotic resistance. Taken together, our current studies provide proof-of-principle, that existing FDA-approved drugs can be further modified and optimized, to successfully target the anchorage-independent growth of CSCs and to prevent the process of spontaneous tumor cell metastasis.
format Online
Article
Text
id pubmed-7523513
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-75235132020-10-09 A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity Ózsvári, Béla Magalhães, Luma G. Latimer, Joe Kangasmetsa, Jussi Sotgia, Federica Lisanti, Michael P. Front Oncol Oncology Here, we describe the chemical synthesis and biological activity of a new Doxycycline derivative, designed specifically to more effectively target cancer stem cells (CSCs). In this analog, a myristic acid (14 carbon) moiety is covalently attached to the free amino group of 9-amino-Doxycycline. First, we determined the IC(50) of Doxy-Myr using the 3D-mammosphere assay, to assess its ability to inhibit the anchorage-independent growth of breast CSCs, using MCF7 cells as a model system. Our results indicate that Doxy-Myr is >5-fold more potent than Doxycycline, as it appears to be better retained in cells, within a peri-nuclear membranous compartment. Moreover, Doxy-Myr did not affect the viability of the total MCF7 cancer cell population or normal fibroblasts grown as 2D-monolayers, showing remarkable selectivity for CSCs. Using both gram-negative and gram-positive bacterial strains, we also demonstrated that Doxy-Myr did not show antibiotic activity, against Escherichia coli and Staphylococcus aureus. Interestingly, other complementary Doxycycline amide derivatives, with longer (16 carbon; palmitic acid) or shorter (12 carbon; lauric acid) fatty acid chain lengths, were both less potent than Doxy-Myr for the targeting of CSCs. Finally, using MDA-MB-231 cells, we also demonstrate that Doxy-Myr has no appreciable effect on tumor growth, but potently inhibits tumor cell metastasis in vivo, with little or no toxicity. In summary, by using 9-amino-Doxycycline as a scaffold, here we have designed new chemical entities for their further development as anti-cancer agents. These compounds selectively target CSCs, e.g., Doxy-Myr, while effectively minimizing the risk of driving antibiotic resistance. Taken together, our current studies provide proof-of-principle, that existing FDA-approved drugs can be further modified and optimized, to successfully target the anchorage-independent growth of CSCs and to prevent the process of spontaneous tumor cell metastasis. Frontiers Media S.A. 2020-09-15 /pmc/articles/PMC7523513/ /pubmed/33042796 http://dx.doi.org/10.3389/fonc.2020.01528 Text en Copyright © 2020 Ózsvári, Magalhães, Latimer, Kangasmetsa, Sotgia and Lisanti. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ózsvári, Béla
Magalhães, Luma G.
Latimer, Joe
Kangasmetsa, Jussi
Sotgia, Federica
Lisanti, Michael P.
A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title_full A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title_fullStr A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title_full_unstemmed A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title_short A Myristoyl Amide Derivative of Doxycycline Potently Targets Cancer Stem Cells (CSCs) and Prevents Spontaneous Metastasis, Without Retaining Antibiotic Activity
title_sort myristoyl amide derivative of doxycycline potently targets cancer stem cells (cscs) and prevents spontaneous metastasis, without retaining antibiotic activity
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523513/
https://www.ncbi.nlm.nih.gov/pubmed/33042796
http://dx.doi.org/10.3389/fonc.2020.01528
work_keys_str_mv AT ozsvaribela amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT magalhaeslumag amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT latimerjoe amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT kangasmetsajussi amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT sotgiafederica amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT lisantimichaelp amyristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT ozsvaribela myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT magalhaeslumag myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT latimerjoe myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT kangasmetsajussi myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT sotgiafederica myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity
AT lisantimichaelp myristoylamidederivativeofdoxycyclinepotentlytargetscancerstemcellscscsandpreventsspontaneousmetastasiswithoutretainingantibioticactivity